
|Articles|December 1, 2002
Anecortave acetate administration shows promise for subfoveal, exudative AMD
San Francisco-The angiostatic steroid anecortave acetate continues to show promise as a safe and effective treatment for subfoveal, exudative age-related macular degeneration (AMD), according to results from an interim analysis of an ongoing phase II trial.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA update: Outlook Therapeutics receives CRL for resubmitted ONS-5010 BLA
2
FDA approvals in 2025: What changed and why it matters for ophthalmologists
3
Innovations in glaucoma poised for breakthrough in 2026 (and what might hold them back)
4
What changed in glaucoma care in 2025: Surgeon perspective
5












































